Back
| Semester | fall semester 2023 |
| Course frequency | Every fall sem. |
| Lecturers |
Christoph Burkhart (christoph.burkhart@unibas.ch)
Thomas Calzascia (thomas.calzascia@unibas.ch) Tobias Junt (tobias.junt@unibas.ch, Assessor) Gisbert Weckbecker (gisbert.weckbecker@unibas.ch) |
| Learning objectives | The student will understand: - Concepts of basic immunology as a prerequisite for discovery of novel targets and drugs - Medical need in key immunological disorders such as multiple sclerosis, lupus and transplant rejection - Discovery, use and limitations of immunosuppressive drugs - Cell depletion strategies to interfere with autoimmune disorders - Discovery of immunomodulatory drugs, e.g. interference with cell migration, co-stimulation and nucleic acid sensing - Immune activation as a successful treatment option for cancer and infection - PI3 kinase inhibitors as an opportunity to interfere with immune disorders or cancer (e.g. idelalisib and duvelisib) |
| Bibliography | Literature List Textbooks (in English): • Kuby Immunology, 8th edition (2018) • Janeway's Immunobiology, 10th edition (2022) • Immunology. A Short Course. 8th Edition (2021), R. Coico G. Sunshine • Cellular and Molecular Immunology, 10th Edition (2021), A. Abbas, A. Lichtman, S. Pillai Check out “Global Immunotalks” on Youtube for related topics Reviews and Papers: Lectures 1 and 2 (Junt) Edner NM, Carlesso G, Rush JS, Walker LSK., Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov. 2020 Dec;19(12):860-883 Junt T, Barchet W (2015), Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol 15, 529 Ley K et al (2016), Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov 15 (3), 173. Chun J, Brinkmann VA (2011), Mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya). Discov Med 12(64), 213. Lectures 3 and 4 (Weckbecker) Waring M et al (2015) An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat Rev Drug Discov, online, 1. Haijuan Y et al (2013) mTOR kinase structure, mechanism and regulation Nature 497, 217. Gurk-Turner,C et al (2012) A Comprehensive Review of Everolimus Clinical Reports: A New Mammalian Target of Rapamycin Inhibitor Transplantation 94, 659. Amber N. Carrier et al (2022) Xenotransplantation: A New Era (Review) Frontiers in Immunology 13, 1-11 B Sharrack, J Petrie, A Coles, JA Snowden (2022) Is stem cell transplantation safe and effective in multiple sclerosis? BMJ, 377. Willison, A.G., Ruck, T., Lenz, G. et al. (2022) The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. J Neurol 269, 3937–3958. Lecture 5 (Burkhart) Vanhaesebroeck B et al (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11(5), 329. Lucas C et al (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 15, 88. Rao VK et al (2017) Effective “activated PI3Kdelta syndrome”-targeted therapy with the PI3Kdelta inhibitor leniolisib. Blood 130, 2307 Vanhaesebroeck B et al (2021) PI3K inhibitors are finally coming of age. Nature Rev Drug Discov 20 (10), 471 Lecture 6 (Calzascia) Ribas A and Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade, Science 359(6382), 1350 Chen DS and Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle, Immunity 39(1): 1. Khalil DN et al (2016) The future of cancer treatment: immunomodulation, CARs and combination therapy, Nat Rev Clin Onc 13, 273. Met Ö et al (2019) Principles of adoptive T cell therapy in cancer, Semin Immunopathol 41(1), 49 |
| Comments | Researchers in Basel have contributed to the fields of immuno-pharmacology (e.g. cyclosporine, everolimus, ofatumumab, ocrelizumab, fingolimod, PI3 kinase inhibitors, diclofenac) and the lecture will refer to some of these discoveries Film and sound recordings during the course are strictly forbidden (recorders may be confiscated) |
| Weblink | Department of Pharmaceutical Sciences |
| Admission requirements | Completed Bachelor degree |
| Language of instruction | English |
| Use of digital media | No specific media used |
| Interval | Weekday | Time | Room |
|---|---|---|---|
| wöchentlich | Wednesday | 10.15-12.00 | Biozentrum, Seminarraum U1.191 |
| Date | Time | Room |
|---|---|---|
| Wednesday 20.09.2023 | 10.15-12.00 | Biozentrum, Seminarraum U1.191 |
| Wednesday 27.09.2023 | 10.15-12.00 | Biozentrum, Seminarraum U1.191 |
| Wednesday 04.10.2023 | 10.15-12.00 | Biozentrum, Seminarraum U1.191 |
| Wednesday 11.10.2023 | 10.15-12.00 | Biozentrum, Seminarraum U1.191 |
| Wednesday 18.10.2023 | 10.15-12.00 | Biozentrum, Seminarraum U1.191 |
| Wednesday 25.10.2023 | 10.15-12.00 | Biozentrum, Seminarraum U1.191 |
| Modules |
Electives Master Science in Pharmacy: Recommendations (Master's Studies: Science in Pharmacy) Module Specialisation: Medical Nanosciences (Master's Studies: Nanosciences) Module: Target Identification/Validation to Discovery of Modulators (Master's Studies: Drug Sciences) |
| Assessment format | continuous assessment |
| Assessment details | refer to this link: https://pharma.unibas.ch/en/education/assessments-and-credit-points/continuous-assessments/ |
| Assessment registration/deregistration | Reg.: course registration, dereg: cancel course registration |
| Repeat examination | no repeat examination |
| Scale | 1-6 0,5 |
| Repeated registration | as often as necessary |
| Responsible faculty | Faculty of Science, studiendekanat-philnat@unibas.ch |
| Offered by | Departement Pharmazeutische Wissenschaften |